Ocular pharmacokinetic studies are key to selecting early compounds or chemical structures for further evaluation and evaluating drug candidates entering clinical trials. Ace Therapeutics offers a variety of preclinical ocular pharmacokinetic, pharmacodynamic and biodistribution research capabilities to meet the specific requirements of each target area of ocular pharmacokinetic research. We support all aspects of ocular PK studies, including study planning and analysis of required samples.
Pharmacokinetics (PK) determines how a drug is absorbed, biodistributed, when it is eliminated from the body, and what it becomes. It is the study of how living organisms affect medicines. In vivo PK studies are critical to ensure that drug candidates have appropriate PK properties that can be assessed in preclinical pharmacology and safety studies. Ocular PK studies provide invaluable information on drug penetration into the eye and its bioavailability in target tissues, as well as how the drug is distributed through ocular tissues, which indicate human equivalent dose (HED), no level of effect (NOEL) and pharmacokinetic/pharmacodynamic (PK/PD) drivers.
With market-leading in vivo PK and ophthalmology expertise, Ace Therapeutics has built a dedicated ocular PK service team. Our experienced and skilled staff can administer drugs to a variety of animals and perform microanatomical analyses of each ocular structure. They can also determine PK profiles and preliminary PK parameters. We provide all aspects of in vivo PK support, including study planning and analysis of required samples. We can deliver them as part of a complete development program, a full-service single study package, or a stand-alone service, in strict compliance with GLP regulations.
To meet the challenging requirements of its diverse clients, Ace Therapeutics has built a team of experienced scientists with facilities and processes specifically designed to deliver optimal strategies and customized protocols to suit any drug discovery program. Our capabilities include:
As part of early pharmacokinetic studies, Ace Therapeutics can microdissect and sample each ocular structure, including:
We can perform in vivo PK studies on a variety of animal species, including:
To support ocular pharmacokinetic studies, Ace Therapeutics' bioanalytical team developed and validated a simple and rapid method using mass spectrometry (RRLC-MS/MS), chromatography (HPLC combined with different detectors), and immunoassays for the quantification of drugs in ocular biological matrices (EIA, RIA, and ELISA).
Ace Therapeutics provides comprehensive ocular pharmacokinetic research methods and integrates them into ophthalmic drug discovery research, resulting in promising results.If you want to know more about lead optimization or have any special needs, please do not hesitate to contact us. Our experienced scientists are ready to help you!